Research programme: melanocortin-4 receptor agonists - Novo Nordisk

Drug Profile

Research programme: melanocortin-4 receptor agonists - Novo Nordisk

Alternative Names: Melanocortin-4 receptor agonists research programme - Novo Nordisk; NNC 70-619; Obesity therapy research programme - Novo Nordisk

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Piperazines; Small molecules
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in Denmark
  • 08 Dec 2004 Data presented at the Annual Scientific Meeting of the North American Association for the Study of Obesity (NAASO-2004) have been added to the adverse events and Obesity pharmacodynamics sections
  • 07 Sep 2004 Preclinical trials in Obesity in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top